Stefan Seuferling (left), the new Chairman of the Executive Board of Raumedic AG, and Martin Bayer, CEO and President of the U.S. business operation, plan to focus more closely on the needs of their target markets. [Image from Raumedic]
Through the re-assignments, executive board member Stefan Seuferling has become chairman of the executive board, which took effect on March 15. Martin Bayer, who was the former chairman, will begin to focus more on his responsibilities as CEO and president of Raumedic’s U.S. market.
Raumedic says that the re-assignments were implemented to improve the position of the company in various medical technology markets.
“Medical technology and the pharmaceutical industry face different requirements in each economic region,” Jürgen Werner, chairman of the board of directors, said in a press release. “In addition, customers are approaching Raumedic with highly individual product requests. With the new management structure, we want to enable both companies to retain their flexibility and to be highly responsive to their respective markets.”
Seuferling joined the company in September last year as the executive board member. He is responsible for strategy and leads sales activities in Europe and Asia. He is also responsible for the departments of marketing communication, quality management, regulatory affairs and projects and services.
Martin Bayer, who moved his office to Mills River, N.C. in early 2018, hopes to generate the same business success that he did for Raumedic’s global organization.
“The new leadership team is the next logical step in our efforts to make Raumedic increasingly agile and market-centric,” Werner said. “We have the utmost confidence in Stefan Seuferling and Martin Bayer. We are certain that they can help the entire company continue generating sustainable and profitable growth. With this goal in mind, they will remain in close dialogue in the future.”
